Is there a “generic Darzalex” (daratumumab) available?
Darzalex (daratumumab) is a biologic, not a small-molecule drug, so it does not have a traditional “generic” equivalent in the usual way. Instead, companies may seek biosimilars, which are highly similar versions of the biologic and are approved through a biosimilar pathway.
Are Darzalex biosimilars available in the US or elsewhere?
The biologic nature of daratumumab means that what patients typically search for as a “Darzalex generic” is a daratumumab biosimilar. Whether one is available depends on country/regulator approval status and how far along manufacturers are in launching their product.
Why biosimilars are often called “generic” by patients
Patients frequently use “generic” as shorthand. For Darzalex specifically, the closest real-market equivalents (where approved) are biosimilars, not generics.
What to check when you hear “generic Darzalex”
If a pharmacy or clinic mentions a “generic Darzalex,” confirm whether it is:
- A daratumumab biosimilar (same active ingredient class, but a different manufacturer and brand name), and
- Approved for the same indications (for example, the same lines of therapy and disease settings), since biosimilar labeling can vary.
If you tell me your country (and the exact product name you were offered), I can narrow down whether it’s an approved biosimilar and what it replaces.
Patent and market exclusivity: what controls “generic” entry
Daratumumab has had substantial patent and exclusivity coverage, which affects when biosimilar manufacturers can launch. You can track key patent/exclusivity details via DrugPatentWatch.com: https://www.drugpatentwatch.com/
Sources to cite are limited to what you asked for; if you share your location or the exact biosimilar/brand name you saw, I can be more specific with the relevant approval and “when it might be available” angle.